TOP 10 COMPANIES IN  NEXT GENERATION SEQUENCING MARKET

The Next Generation Sequencing Market is Projected to Reach $27.5  billion by 2030, at a CAGR of 15.8% During the Forecast Period, Says Meticulous Research^®. Next Generation Sequencing (NGS) is a technology used to sequence the orientation of nucleotides in genetic material. This technology enables the sequencing of DNA or RNA more quickly and at a lower cost than Sanger sequencing. Technological advancements in sequencing procedures, a surge in genome mapping programs, an increase in drug discovery platforms demanding NGS technology, and declining cost of genome sequencing are the key factors driving the global NGS market.

Here are the top 10 companies operating in the Next Generation Sequencing Market

Illumina, Inc.(U.S.)

Incorporated in 1998 and headquartered in California, U.S., Illumina is a provider of sequencing- and array-based solutions for genomic and genetic analysis. The company operates through two reportable segments, namely, Core Illumina and GRAIL. The Core Illumina segment offers a wide range of NGS solutions to simplify workflows and accelerate analysis.

Illumina provides its products to government laboratories, genomic research centers, academic institutions, hospitals, commercial molecular diagnostics laboratories, and pharmaceutical and consumer genomics companies. The company has manufacturing sites and laboratories in the U.S., Singapore, and the U.K.

Illumina distributes its products globally in North America, Europe, Latin America, Asia-Pacific, and the Middle East & Africa through its distributors. Some of its subsidiaries operating in the NGS market are Illumina GmbH (Germany), Illumina Australia Pty. Ltd. (Australia), Illumina UK, Ltd. (U.K.), Illumina Italy S.r.l. (Italy), Illumina Netherlands B.V. (Netherlands) and Illumina K.K. Japan (Japan).

Thermo Fisher Scientific, Inc.  (U.S.)

Founded in 1956 and headquartered in Massachusetts, U.S., Thermo Fisher offers products and services in the pharmaceutical, biotechnology, agricultural, clinical, healthcare, government, and academic sectors. The company operates through four segments, namely, Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Biopharma Services. The Life Sciences Solutions segment offers NGS products such as Ion GeneStudio S5 System and Ion Torrent Genexus System.

Thermo Fisher has a strong geographic presence across North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa through its subsidiaries, R&D sites, and a strong distribution network. As of December 2022, the company had a headcount of 130,000 employees, of which 67,000 were employed in the Americas, 21,000 in Asia-Pacific, and 42,000 in Europe and the Middle East & Africa. Some of its major subsidiaries are Molecular Probes, Inc. (U.S.), Thermo Electron North America LLC (U.S.), Thermo Foundation, Inc. (U.S.), European Laboratory Holdings Limited (U.K.), and Patheon France SAS (France).

Beijing Genomics Institute (BGI) (China)

Established in 1999 and headquartered in Shenzhen, China, BGI is a provider of proteomics and genomics sequencing services. The company provides various integrated genomic sequencing and proteomic solutions and services for pharmaceutical companies, medical institutions, healthcare providers, and other organizations.

BGI PROVIDES its offerings to over 100 countries globally. As of 2021, the company had a headcount of 6,000 employees. Most of the sequencing solutions of the company are done on the DNBSEQ NGS platform. The company has offices located in Denmark, the U.S., China, and Japan.

Qiagen N.V. (Netherlands)

Founded in 1984 and headquartered in Venlo, Netherlands, Qiagen N.V. is one of the leading providers of sample and assay technologies for molecular diagnostics, applied testing, and academic and pharmaceutical research. The company offers its products through only one reportable segment and provides them in two major markets: Molecular Diagnostics and Life Sciences.

Qiagen’s product offerings include diagnostic solutions, PCR products, genomic or NGS products, consumables and instruments for sample technologies. Further, the company offers more than 500 core products consisting of instruments, kits, bioinformatics solutions, and a wide range of NGS services, such as RNA sequencing services, DNA sequencing services, whole genome amplification services, and RNA isolation services, among others. These NGS offerings are offered under the Genomics/NGS products category.

The company markets its products in more than 130 countries across the globe. The company has facilities located in the U.S., China, Germany, Poland, the Philippines, Denmark, Romania, Spain, the U.K., and other countries. Furthermore, the company’s sales are handled by distributors and sales subsidiaries. It also sells products directly to customers. In the Americas, Europe, Asia, and Australia, the subsidiaries mainly take care of sales. Some of the major subsidiaries of the company are Qiagen AB (Sweden), Qiagen Instruments AG (Switzerland), Qiagen GmbH (Germany), QIAGEN LLC (U.S.), QIAGEN China (Shanghai) Co. Ltd. (China), QIAGEN Inc. (Canada), QIAGEN K.K. (Japan), and QIAGEN S.r.l. (Italy). As of December 2020, the company had employed over 902 personnel for R&D.

Hoffmann-La Roche Ltd (Switzerland)

Founded in 1896 and headquartered in Basel, Switzerland, Roche is a healthcare company that develops, manufactures, and markets a wide range of healthcare solutions. The company operates through two reportable divisions, namely, Pharmaceuticals and Diagnostics, of which the Diagnostics division operates in the NGS market.

The Diagnostics division is engaged in developing a wide range of diagnostic products and solutions such as in vitro diagnostics solutions, molecular diagnostics, clinical chemistry & immunoassays, point-of-care testing, tissue diagnostics, patient self-testing, next-generation sequencing, laboratory automation and IT, and decision support solutions.

Roche has a geographic presence across the U.S., Germany, Switzerland, Japan, China, India, New Zealand, Australia, Latin America, and Africa. Furthermore, the company has 23 manufacturing sites and 29 research and development sites worldwide. Some of its subsidiaries are Roche Diagnostics (U.S.), Roche Diagnostics GmbH (Germany), Roche Diagnostics France SAS (France), Roche Diagnostics S.p.A. (Italy), Roche Diagnostics International AG (Switzerland), Roche Diagnostics Limited (U.K.), Roche Diagnostics (Shanghai) Ltd. (China), and Roche Diagnostics K.K (Japan).

Meticulous Research in its latest publication on Next Generation Sequencing (NGS) Market has predicted the growth of 15.8% during the forecast year 2023-2030.

PerkinElmer, Inc. (U.S.)

Founded in 1937 and headquartered in Massachusetts, U.S., PerkinElmer is a multinational company that offers products, solutions, and services for the life sciences, diagnostics, and applied markets. It operates through two reportable business segments: Discovery & Analytical Solutions and Diagnostics. The Diagnostics business segment offers NGS offerings.

The company’s manufacturing and R&D facilities are located in several countries, including the U.S., China, Japan, and Germany. Furthermore, the company has a strong network of sales and marketing channels and service personnel in over 38 countries and sells its products and services in over 190 countries.

PerkinElmer sells products and services predominantly through its distributors. Some of its subsidiaries are PerkinElmer Genetics, Inc. (U.S.), PerkinElmer Pty. Ltd. (Australia), PerkinElmer do Brasil Ltda. (Brazil), PerkinElmer Instruments (Shanghai) Co. Ltd. (China), PerkinElmer SAS (France), PerkinElmer Technologies GmbH & Co. KG (Germany), PerkinElmer Srl (Italy), PerkinElmer (India) Pvt Ltd. (India), and PerkinElmer Sverige AB (Sweden).

Agilent Technologies, Inc. (U.S.)

Founded in 1999 and headquartered in California, U.S., Agilent Technologies provides application-focused solutions to the life sciences, diagnostics, and applied chemical markets. The company operates through three business segments: Life Sciences and Applied Markets; Agilent CrossLab; and Diagnostics and Genomics. The Diagnostics and Genomics segment offers the NGS products market.

Agilent has a presence across North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa and customers in over 110 countries through its subsidiaries and a strong distribution network. The company has research & development and manufacturing sites in California, Colorado, Delaware, Massachusetts, Texas, Vermont, Washington, Australia, China, Denmark, Germany, Italy, Japan, Malaysia, Singapore, and the U.K.

Some of the company’s subsidiaries are Agilent Technologies Canada Inc. (Canada), Agilent Technologies UK Limited (U.K.), Agilent Technologies Deutschland GmbH (Germany), Agilent Technologies Company Limited (China), Agilent Technologies Japan, Ltd (Japan), Agilent Technologies Brasil Ltda. (Brazil), and Agilent Technologies France SAS (France).

Pacific Biosciences of California, Inc.  (U.S.)

Incorporated in 2004 and headquartered in California, U.S., Pacific Biosciences of California is a life science technology company that designs, develops, and manufactures advancing sequencing solutions that help researchers and scientists solve genetically complex problems. The company focuses on two core technologies: HiFi long-read sequencing technology and short read Sequencing by Binding (SBB) technology. Pacific Biosciences’ products address solutions to various applications, including plant and animal sciences, human germline sequencing, oncology, infectious disease and microbiology, and other emerging applications.

Pacific Biosciences operates through a single business segment and provides its products to various end users such as governmental and academic research institutions, service laboratories and commercial testing, genome centers, hospitals and clinical research institutions, public health labs, contract research organizations (CROs), and agricultural and pharmaceutical companies.

The company has a direct presence across the U.K. in Europe, China, Japan, South Korea, Singapore, Asia-Pacific, and the Middle East & Africa.

Danaher Corporation (U.S.)

Founded in 1984 and headquartered in Washington, D.C., U.S., Danaher Corporation designs, manufactures, and markets medical, professional, industrial, and commercial products and services for various end users. The company operates through four reportable business segments, namely, Life Sciences, Biotechnology, Diagnostics, and Environmental & Applied Solutions. In March 2018, Danaher Corporation acquired Integrated DNA Technologies, Inc. (U.S.) to expand its presence in genomics research.

The Life Sciences segment offers products for the NGS market. The company has research and development, manufacturing, sales, distribution, service, and administrative facilities in more than 60 countries across the globe. Danaher Corporation sells its products through direct sales personnel and independent distributors.

Some of Danaher Corporation’s subsidiaries offering NGS products are Beckman Coulter, Inc. (U.S.) and Integrated DNA Technologies, Inc. (U.S.). Some of its other subsidiaries are Beckman Coulter Biomedical Ltd. (Ireland), Beckman Coulter Commercial Enterprise Co., Ltd. (China), Beckman Coulter France S.A.S. (France), Beckman Coulter GmbH (Germany), Beckman Coulter United Kingdom (U.K.), Beckman Coulter India Pvt Ltd (India), Beckman Coulter Australia Pty. Ltd. (Australia), Beckman Coulter Korea Ltd. (South Korea).

Oxford Nanopore Technologies Plc. (U.K.)

Founded in 2005 and headquartered in England, U.K., Oxford Nanopore Technologies Plc. is a manufacturer of devices that sequence DNA/RNA directly. The company’s principal activities are to research, develop, manufacture, and commercialize a nanopore-based sequencing platform that allows real-time analysis of DNA or RNA.

Oxford Nanopore’s offerings enable customers to perform scientific/biomedical research in multiple application areas, including environmental analysis, cancer research, human genetics, pathogens/antimicrobial resistance, viral outbreak surveillance, microbiome analysis and crop science. Furthermore, the company operates its business in two reporting segments, namely, Life Science Research Tools (LSRT) and Non-recurring Covid testing revenue. The Life Science Research Tools business segment offers NGS products to universities, commercial laboratories, and industrial or government research laboratories and provides sequencing to scientists. The company operates its businesses in more than 120 countries.

Authoritative Research on the Next Generation Sequencing (NGS) Market – Global Opportunity Analysis and Industry Forecast (2023-2030)

Need more information? Meticulous Research®’s new report covers each of these companies in much more detail, providing analysis on the following:

• Recent financial performance
• Key products
• Significant company strategies
• Partnerships and acquisitions

The Comprehensive report provides global market size estimates, market share analysis, revenue numbers, and coverage of key issues and trends.